Ken Griffin Gossamer Bio, Inc. Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Gossamer Bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 122,500 shares of GOSS stock, worth $187,425. This represents 0.0% of its overall portfolio holdings.

Number of Shares

122,500

Previous 94,700 29.36%

Holding current value

$187,425

Previous $93,000 18.28%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$0.66 - $1.07 $594,030 - $963,049	-900,046 Reduced 86.54%	140,007 $126,000
Q3 2024 Nov 14, 2024	SELL	$0.79 - $1.25 $2.41 Million - $3.82 Million	-3,053,783 Reduced 74.59%	1,040,053 $1.03 Million
Q2 2024 Aug 14, 2024	BUY	$0.51 - $1.27 $111,746 - $278,269	219,110 Added 5.65%	4,093,836 $3.68 Million
Q1 2024 May 15, 2024	SELL	$0.8 - $1.51 $1.81 Million - $3.42 Million	-2,265,506 Reduced 36.9%	3,874,726 $4.57 Million
Q4 2023 Feb 14, 2024	SELL	$0.48 - $1.08 $13,397 - $30,143	-27,911 Reduced 0.45%	6,140,232 $5.59 Million
Q3 2023 Nov 14, 2023	BUY	$0.78 - $1.82 $3.7 Million - $8.63 Million	4,741,674 Added 332.41%	6,168,143 $5.12 Million
Q2 2023 Aug 14, 2023	SELL	$0.98 - $1.53 $1.34 Million - $2.09 Million	-1,368,248 Reduced 48.96%	1,426,469 $1.71 Million
Q1 2023 May 15, 2023	BUY	$0.96 - $2.92 $2.68 Million - $8.16 Million	2,794,717 New	2,794,717 $3.52 Million
Q3 2022 Nov 14, 2022	SELL	$7.21 - $14.88 $11.2 Million - $23.1 Million	-1,551,585 Reduced 67.97%	731,264 $8.76 Million
Q2 2022 Aug 15, 2022	BUY	$5.97 - $9.97 $827,071 - $1.38 Million	138,538 Added 6.46%	2,282,849 $19.1 Million
Q1 2022 May 16, 2022	BUY	$8.44 - $12.49 $2.27 Million - $3.35 Million	268,560 Added 14.32%	2,144,311 $18.6 Million
Q4 2021 Feb 14, 2022	BUY	$10.12 - $14.07 $2.91 Million - $4.05 Million	287,800 Added 18.12%	1,875,751 $21.2 Million
Q3 2021 Nov 15, 2021	BUY	$7.25 - $13.23 $11.4 Million - $20.8 Million	1,572,150 Added 9949.69%	1,587,951 $20 Million
Q2 2021 Aug 16, 2021	SELL	$8.0 - $9.75 $4.52 Million - $5.51 Million	-564,995 Reduced 97.28%	15,801 $128,000
Q1 2021 May 17, 2021	SELL	$8.63 - $10.94 $1.64 Million - $2.08 Million	-189,962 Reduced 24.65%	580,796 $5.37 Million
Q4 2020 Feb 16, 2021	BUY	$8.3 - $13.59 $5.74 Million - $9.39 Million	691,286 Added 869.85%	770,758 $7.45 Million
Q3 2020 Nov 16, 2020	BUY	$11.3 - $14.75 $376,131 - $490,968	33,286 Added 72.07%	79,472 $986,000
Q2 2020 Aug 14, 2020	SELL	$9.52 - $15.98 $2.55 Million - $4.29 Million	-268,266 Reduced 85.31%	46,186 $600,000
Q1 2020 May 15, 2020	BUY	$8.0 - $15.48 $2.18 Million - $4.22 Million	272,828 Added 655.46%	314,452 $3.19 Million
Q4 2019 Feb 14, 2020	SELL	$14.82 - $26.79 $13.1 Million - $23.6 Million	-881,320 Reduced 95.49%	41,624 $650,000
Q3 2019 Nov 14, 2019	SELL	$16.02 - $22.47 $63,727 - $89,385	-3,978 Reduced 0.43%	922,944 $15.5 Million
Q2 2019 Aug 14, 2019	SELL	$16.12 - $22.89 $735,894 - $1.04 Million	-45,651 Reduced 4.69%	926,922 $20.6 Million
Q1 2019 May 15, 2019	BUY	$17.58 - $23.97 $17.1 Million - $23.3 Million	972,573 New	972,573 $0

Others Institutions Holding GOSS

# of Institutions

116

Shares Held

163M

Call Options Held

821K

Put Options Held

557K

View Full List

About Gossamer Bio, Inc.

Ticker GOSS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,954,000
Market Cap $144M
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...

More about GOSS

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account